Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease
Clicks: 484
ID: 116637
1985
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
484 views
63 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #12 of 149 articles by views in JAMA
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 149 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Aerosolized ribavirin was evaluated in the treatment of respiratory syncytial virus lower respiratory tract disease in 53 infants, 36 of whom had underlying diseases. Of the total infants, 26 were studied in a double-blind, placebo-controlled manner; 14 received ribavirin and 12 received placebo, a …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (39 words).
Try re-searching for a better abstract.
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.